PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$3.23
+0.07 (+2.22%)
Open$3.24
Previous Close$3.16
Day High$3.37
Day Low$3.10
52W High$6.94
52W Low$1.56
Volume—
Avg Volume2.88M
Market Cap583.39M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Buy
19 analysts
Price Target
+1,237.2% upside
Current
$3.23
$3.23
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.74M | 5.54M | 80.41M |
| Net Income | -249,622,626 | -327,047,779 | -21,315,556 |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% |
| EBITDA | -249,493,393 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | — | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |